Emberley, E., Pan, A., Chen, J., Dang, R., Gross, M., Huang, T., . . . Parlati, F. (2021). The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma. Public Library of Science (PLoS).
Cita Chicago Style (17a ed.)Emberley, Ethan, et al. The Glutaminase Inhibitor Telaglenastat Enhances the Antitumor Activity of Signal Transduction Inhibitors Everolimus and Cabozantinib in Models of Renal Cell Carcinoma. Public Library of Science (PLoS), 2021.
Cita MLA (8a ed.)Emberley, Ethan, et al. The Glutaminase Inhibitor Telaglenastat Enhances the Antitumor Activity of Signal Transduction Inhibitors Everolimus and Cabozantinib in Models of Renal Cell Carcinoma. Public Library of Science (PLoS), 2021.